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Yaron Sternbach, MD, Kathleen J. Ozsvath, MD, Paul B. Kreienberg, MD, and
Philip S. K. Paty, MD, Albany, NY
Objective: Successful thoracic endovascular aneurysm repair (TEVAR) requires adequate proximal and distal fixation and
seal. We report our experience of planned celiac artery coverage during endovascular repair of complex thoracic aortic
aneurysms (TAA).
Methods: Since 2004, 228 patients underwent TEVAR under elective (n  162, 71%) and emergent circumstances (66,
29%). Patients with inadequate distal stent grafts landing zones during TEVAR underwent detailed evaluation of the
gastroduodenal arcade with communicating collaterals between the celiac and superior mesenteric artery (SMA) by
computed tomography angiography and intraoperative arteriogram. If needed, in presence of a patent SMA and
demonstration of collaterals to the celiac artery, the stent grafts were extended to the SMA with celiac artery coverage.
Furthermore, instances when further lengthening of distal thoracic stent graft landing zone was needed to obtain an
adequate seal, the SMA was partially covered with the endograft, and a balloon expandable stent was routinely deployed
in proximal SMA to maintain patency. Outcome data were prospectively collected and analyzed retrospectively.
Results: Thirty-one of 228 (14%) patients with TEVAR required celiac artery interruption; 24 (77%) had demonstrable
collaterals to the SMA. Twelve (39%) of 31 patients underwent additional partial SMA coverage by stent graft, and
proximal SMA stent. The majority of patients were females (n 20, 65%), the mean age was 74 years (range 55-87 years),
and the mean TAA size was 6.5 cm. Postoperative complications included visceral ischemia in 2 (6%) patients, paraplegia
in 2 (6%) patients, and death in 2 (6%) patients. All type 1b endoleaks (n  2, 6%) and type 2 endoleaks vial retrograde
flow from the celiac artery (n  3, 10%) were successfully treated by transfemoral coil embolization. Over a mean
follow-up of 15 months, there have been no other complications of mesenteric ischemia, spinal cord ischemia, SMA
in-stent stenosis, or conversion to open surgical repair.
Conclusions: Our findings suggest that celiac artery coverage to facilitate adequate distal sealing during TEVAR with
complex TAA is relatively safe in the presence of SMA-celiac collaterals. Pre-existing SMA stenosis can be successfully
treated by balloon expandable stents during TEVAR, and endoleaks arising from distal stent grafts attachment site or via
retrograde flow from the celiac artery can be successfully managed by transfemoral coil embolization. Although early
results are encouraging, long-term efficacy of these procedures remains to be determined and vigilant follow-up is needed.
(J Vasc Surg 2010;52:1153-8.)It has been over a decade since the introduction of
thoracic endovascular aneurysm repair (TEVAR), and to-
day there is ample evidence suggesting early and midterm
advantages of this endovascular procedure over the tradi-
tional open thoracic aortic reconstruction in anatomically
suitable patients.1-3 Anatomically suitability during TEVAR
implies that patients with descending thoracic aortic aneu-
rysms (TAA) have adequate proximal and distal thoracic
stent graft landing zones, which according to “instructions
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doi:10.1016/j.jvs.2010.06.105for use” of thoracic stent grafts, would include a 2 cm
aneurysm free normal thoracic aorta distal to the left com-
mon carotid artery, and similarly a 2 cm aneurysm free
normal thoracic aorta proximal to the celiac artery. Al-
though extensions of the proximal thoracic stent graft
landing zones that include coverage of the left subclavian
artery with or without extra-anatomic left carotid-subcla-
vian bypass, or even the left carotid artery coverage with
extra-anatomic right to left carotid-carotid and left carotid-
subclavian bypass have been considered relatively safe,
other extra-anatomic visceral reconstructions that include
celiac/superior mesenteric bypass or “debranching” to ex-
tend the distal landing zones have been associated with
significant morbidity and mortality.4
The importance of collateralization through the vis-
ceral arterial tree has been well understood, and it is rare
for symptoms of visceral/intestinal ischemia to develop
with stenosis or even occlusion of one of the mesenteric
arteries.5 There are several important collateral pathways
between the celiac and the superior mesenteric artery that
supply blood flow to the abdominal viscera, and when
either of these two arteries is narrowed or occluded the
collateral pathways across the pancreaticoduodenal arteries
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artery, blood flow to the liver, spleen, stomach, and duo-
denum precedes from the superior mesenteric artery
(SMA) to the pancreaticoduodenal collaterals to the he-
patic artery. Furthermore, the incidence of a replaced right
hepatic artery that originates from the SMA is 15% to 20%,
which helps provide collateral blood flow between the two
visceral arteries.6
When dealing with TAA, in the “real world” clinical
scenarios, patients sometimes present with extensive aneu-
rysmal involvement that extends up to the distal thoracic
aorta, precluding an adequate distal stent graft landing
zone, and coverage of the celiac artery to facilitate adequate
stent graft fixation and seal is necessary. Visceral artery
revascularizations during TEVAR are complex procedures
and their associated morbidity and mortality. In light of the
complexity of visceral revascularization in TAA patients,
and the fact that the celiac and the SMA have a rich
collateral network has set the stage for us to evaluate the
feasibility and efficacy of celiac artery coverage without
revascularization during TEVAR. We report our experience
of planned celiac artery coverage during endovascular re-
pair of complex TAA.
METHODS
Our initial TEVAR experience began in 2004, and
since, 228 patients underwent TEVAR for treatment of
lesions in the thoracic aorta. Early in our experience,
TEVAR was performed for patients with distal stent graft
landing zone of at least 2 cm, in accordance with the
“indications for use” of the FDA approved and commer-
cially available thoracic stent grafts. As our experience
evolved and we were faced with patients with complex TAA
that extended up to the celiac artery, we were forced to
evaluate the outcomes of celiac artery coverage during
TEVAR in treating these high-risk patients.
Patients with large fusiform TAA 6 cm, or saccular
TAA irrespective of size, with inadequate distal stent
graft landing zones above the celiac artery underwent a
detailed evaluation of the gastroduodenal collateral cir-
culation between the SMA and the celiac artery by compu-
ted tomography angiography (CTA). When CTA was
non-demonstratable for gastroduodenal collaterals or failed
to indicate aberrant replaced right hepatic artery originat-
ing from the SMA, preoperative and/or intraoperative
selective arteriogram was performed to further delineate
the existence of these collaterals. The arteriogram was
obtained in the anterior-posterior as well as lateral projec-
tions, and when selective catheterization failed to indicate
gastroduodenal-pancreaticoduodenal collaterals, tempo-
rary celiac artery occlusion with a 5 to 6 mm balloon was
obtained prior to superior mesenteric arteriogram.
Patients considered high risk for open surgical thoraco-
abdominal aortic reconstructions were considered for
TEVAR with coverage of celiac artery to achieve a seal at
the distal stent graft landing zone. TEVAR procedures
were performed using general or spinal anesthesia using
TAG thoracic stent graft (WL Gore & Associates, Flagstaff,Ariz), or Talent thoracic stent graft (Medtronic Ave, Santa
Rosa, Calif). Cerebral spinal fluid (CSF) drainage was used
selectively, and in general reserved for patients with prior
abdominal aortic reconstructions via open surgical or en-
dovascular means, or in patients that required extensive
coverage of the thoracic aorta during TEVAR. The se-
quence of placement of the thoracic stent grafts be it
proximal to distal or vice versa was up to the discretion of
the vascular surgeon. Patients with celiac artery stent graft
coverage that presented with critical SMA stenosis or when
further lengthening of the distal thoracic stent graft landing
zone was needed to obtain an adequate seal and the SMA
was partly covered with the stent graft, access into the SMA
was obtained via a 6F guide sheath or a 4 to 5 mm balloon
catheter prior to stent graft deployment, and subsequently,
a balloon expandable stent was routinely deployed in the
proximal SMA to maintain patency. (Fig 1, A, B, and C)
At the completion of TEVAR, patient assessment in-
cluded an arteriogram to identify distal stent graft seal, with
careful evaluation for the presence of distal type Ib en-
doleak, or type II endoleak via retrograde flow into the
TAA from the celiac artery, and for patency of the SMA.
During the postoperative period, clinical parameters sug-
gesting presence of visceral ischemia or malperfusion were
evaluated, including the development of lactic acidosis,
leukocytosis, fever, and abdominal pain. Postoperative
follow-up included routine clinical evaluation at 1 month
and every 6 months thereafter, and initial CTA at 1 month,
6 months, 12 months, and yearly thereafter (Fig 2). During
follow-up, any endoleaks noted at the distal thoracic aortic
stent graft attachment site were treated by coil emboliza-
tion procedures. By means of a transfemoral approach, a
guide catheter was traversed across the distal stent graft
attachment site in between the stent graft and the thoracic
aortic wall. The catheter was advanced into the distal tho-
racic aortic aneurysm and coils were placed in proximity to
the celiac artery, or the site of the endoleak channel. (Fig 3,
A, B, and C) All data were prospectively collected in a
vascular registry and Institutional Review Board approval
was obtained for evaluation of all patient outcomes data.
RESULTS
Over a 5-year period, 31 (14%) of 228 patients with
TEVAR required celiac artery stent graft coverage, and 12
(39%) of these 31 patients required additional partial cov-
erage of the SMA. All 12 patients with complete celiac
artery coverage and partial SMA coverage underwent bal-
loon expandable stent placement in the SMA. None of the
patients had both complete celiac artery and SMA cover-
age.
The demographics and operative findings are listed in
Table I; the majority of patients were females (65%), the
mean age was 74 years (range 55-87 years), the mean TAA
size was 6.5 cm (range 5.4 cm-8.2 cm) and comparable
among both genders, and the mean estimated blood loss
was 379 cc. During the postoperative period, on postoper-
ative day 1 complications of visceral ischemia developed in
two patients (6%); one patient developed shock liver and
the SM
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ization, and died. A preoperative CTA indicated gastrodu-
odenal collateral pathways between the celiac artery and the
SMA. The TEVAR procedure required stent graft coverage
from distal to the subclavian artery to just above the SMA,
Fig 1. A, Celiac artery stent graft coverage (thick ar
mesenteric artery (SMA) stent (arrow) during thoracic en
graft coverage. C, Following SMA stent, marked enhanc
network (arrows) supplying the celiac artery catheter in
Fig 2. Origin of celiac artery coverage with thoracic stent graft,
patent superior mesenteric artery (SMA) with collaterals to the
celiac artery.the operative blood loss was 250 cc, the procedure time was50 minutes, and was considered uneventful. A second
patient developed acalculus cholecystitis and underwent a
successful open surgical cholecystectomy. One other pa-
tient developed ischemic colitis affecting the sigmoid co-
lon; at the time of sigmoid resection, the stomach, small
bowel, and the proximal colon were not ischemic. Intraop-
erative findings also indicated antegrade pulsatile flow in
the SMA, retrograde pulsatile flow in the celiac via well-
developed collaterals, and the ischemic sigmoid colitis was
considered to be embolic and not related to celiac artery
coverage. Two (6%) patients developed paraplegia; one had
a prior infrarenal abdominal aortic aneurysm repair 3 years
prior to TEVAR, and underwent CSF drainage. On post-
operative day 1, the CSF drain malfunctioned, and the
patient developed symptoms of spinal cord ischemia that
were irreversible. The second patient had TEVAR for a
complex TAA with coverage of the left subclavian artery
and a carotid-subclavian polytetrafluoroethylene (PTFE)
bypass. The procedure time was approximately 230 min-
utes, the operative blood loss of 1250 cc, and the patient
had iliac artery rupture during TEVAR requiring emergent
iliofemoral bypass. The 30-day operative mortality was 6%;
one patient died with complications of visceral ischemia,
and second patient suffered complications of myocardial
infarction (Table II).
During the postoperative follow-up, endoleaks were
noted on CTA evaluations in 9 (29%) patients; 4 (13%)
patients had type II endoleaks from intercostal arteries, 3
(10%) patients had a type II endoleak via retrograde flow
from the celiac artery, and 2 (6%) patients had a type Ib
endoleak from distal stent graft attachment site. All five
(16%) patients with endoleaks from retrograde flow via the
and critical SMA stenosis (thin arrow). B, Superior
scular aneurysm repair (TEVAR) with celiac artery stent
t of gastroduodenal and pancreatiocduodenal collateral
A.row)
dova
emenceliac artery or from the distal stent graft attachment site
of T
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follow-up of 15 months, two (6%) patients with stent graft
migration from distal attachment site required additional
stent graft extensions. Over a mean follow-up of 15
months, there have been no other complications of mesen-
teric ischemia, spinal cord ischemia, SMA in-stent stenosis,
or conversion to open surgical repair.
DISCUSSION
TEVAR has evolved to become a viable option for
treatment for aortic lesions that affect the descending tho-
racic aorta. When thoracic aneurysms are extensive and
expand beyond the limitations of currently available tho-
racic endoprosthesis, surgeons and interventionalists are
often forced to make improvements that are technically and
technologically driven to facilitate repair of these complex
and extensive aneurysms that if untreated or treated by
surgical reconstruction are associated with a significant
morbidity and mortality.7,8 In evaluating our single center
Table I. Patient demographics
TEVAR with celiac artery
coverage 31
Male/female 11 (35%), 20 (65%)
Mean age 74.2 years
Mean TAA size 6.5 cm (range 5.4 cm-8.2 cm)
Coronary artery disease 18 (58%)
Hypertension 28 (90%)
Chronic obstructive pulmonary
disease 12 (39%)
Pre-existing renal failure
(dialysis) 4 (12%)
Mean estimated blood loss 379 cc
TAA, Thoracic aortic aneurysms; TEVAR, thoracic endovascular aneurysm
repair.
Fig 3. A, Type Ib endoleak (arrow) from stent graft di
type Ib endoleak channel. C, Coil embolization (arrow)experience of 31 TEVAR patients with intentional celiacartery coverage, the findings suggest that the incidence of
complications of visceral ischemia in these patients is 6%,
and the incidence of death with associated visceral ischemia
is 3%. With celiac artery coverage during TEVAR, the
overall potential for any possible complications of visceral
ischemia can occur in 16% (5/31) of the patients. In
considering the alternative of treating patients that would
otherwise require surgical thoracoabdominal aortic recon-
structions or hybrid endovascular procedures with surgical
visceral artery debranching, the morbidity and mortality of
intentional celiac artery coverage during TEVAR in pa-
tients that on CTA and/or arteriography have demon-
strated the presence of visceral collateral pathways between
the celiac and the SMA would seem acceptable.
Although our experience of intentional celiac artery
coverage to facilitate distal stent graft seal zone during
TEVAR is the largest to-date, several other centers have
published data with comparable results.9-11 Their findings
also suggest the feasibility and short-term efficacy of celiac
Table II. Complications in TEVAR patients with celiac
coverage
TEVAR with celiac artery
coverage 31 Outcome
Visceral ischemia 2 (6%)
- Shock liver 1 (3%) Death
- Acalculus cholecystitis 1 (3%) Cholecystectomy
Paraplegia 2 (6%) 1 death
30-day mortality 2 (6%)
Type 1b endoleak @ distal
attachment site 2 (6%) Coil embolization
Type II endoleak: celiac artery
retrograde flow 3 (10%) Coil embolization
TEVAR, Thoracic endovascular aneurysm repair.
nding zone. B, Transfemoral guide catheter access into
ype Ib endoleak via transfemoral guide catheter.stal laartery stent graft coverage to facilitate TEVAR with a caveat
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readily predict the complications of visceral ischemia. When
planning celiac artery coverage during TEVAR for complex
thoracic aortic aneurysms that with limited distal suprace-
liac stent graft landing zone, several assertions can be made
based on the currently available data, these include: (1) a
thorough evaluation of the celiac and SMA collaterals via
CTA and/or arteriography, (2) treatment of coexisting
critical SMA occlusive disease, (3) objective evaluation of
subtle signs and symptoms of mesenteric ischemia during
the perioperative period, and (4) consideration for cerebral
spinal fluid drainage.
A thorough evaluation of the celiac and SMA collaterals
via CTA and/or arteriography should be considered essen-
tial prior to planning TEVAR and celiac artery coverage.
Studies evaluating CTA and standard arteriography have
indicated that the accuracy of CTA for depicting visceral
arterial anatomy and identifying branches of the gastrodu-
odenal and pancreaticodudenal arteries that are the collat-
eral communications between the celiac and the SMA is
90%.12 Of course, CTA and even arteriography only
indicate the mere presence of collaterals and do not allow
for assessment of the direction of blood flow. When CTA
fails to demonstrate visceral collaterals between the celiac
and the SMA, selective arteriogram is necessary and often
requires temporary occlusion of the celiac artery with a 5 to
6 mm balloon catheter prior to selective superior mesen-
teric arteriography to assess the visceral collaterals.
Coexisting occlusive disease in the SMA should be
evaluated via angiography prior to stent graft deployment.
Instances when celiac artery coverage with stent graft is
needed and the presence of severe SMA occlusive disease is
identified, even when asymptomatic, placement of a bal-
loon expandable stent in the SMA should be considered.
Theoretically, this could help prevent mesenteric/visceral
ischemia that might otherwise develop in patients as their
abdominal organs rely on the SMA with critical stenosis as
the sole blood supply. In our experience, 39% of the pa-
tients with celiac artery coverage had either coexisting
severe SMA occlusive disease or partial stent graft coverage
of the SMA, and underwent balloon expandable stent
placement to maintain patency of the SMA. We have no
comparative data to evaluate what might the outcomes
have been if the SMA did not undergo stent placement;
however, since none of these patients have developed
symptoms of visceral ischemia, we have continued to em-
ploy this strategy when managing these complex TAAs.
Preoperative evaluation of patient for the presence of
symptoms of chronic mesenteric ischemia, as subtle as they
might be, should be thoroughly evaluated prior to embark-
ing on these procedures. Although we did not experience
this in our patients, we would recommend routine gastro-
intestinal workup by a gastroenterologist including endos-
copy, CTA, and preoperative angiography in select patients
as needed. Furthermore, during the postoperative period,
signs and symptoms of mesenteric ischemia should be
carefully evaluated by subjective clinical examinations, as
well as objective data such as assessment of leukocytosis,lactic acidosis, elevation of amylase/lipase, and liver func-
tion tests. Finally, patients that develop signs and/or symp-
toms of visceral ischemia should undergo prompt visceral
revascularization.
Placement of cerebral spinal fluid (CSF) drainage cath-
eters should be considered in these patients since these
procedures require significant coverage of the thoracic
aorta, and the distal extent of the stent grafts usually
extends to the T12-L1 level, which could potentially also
cover the artery of Adamkiewicz.13,14 Although the etiol-
ogy for developing complications of spinal cord ischemia
(SCI) during TEVAR are multifactorial and not necessarily
just related to coverage of the artery of Adamkiewicz,
significant coverage of the thoracic aorta during TEVAR
does increase the risk for developing SCI and should be
evaluated during these procedures.
Finally, CTA alone might be inadequate in differenti-
ating between a type Ib endoleak (inadequate distal stent
graft seal) and a type II endoleak (persistent retrograde
celiac artery flow into the TAA), and selective transfemoral
angiography if often needed to differentiate between the
endoleak types. In such instances, when postoperative CTA
suggests an endoleak in proximity to the distal stent graft
attachment site, selective SMA catheterization and arterio-
gram with anterior-posterior and lateral imaging can be
used to identify type II endoleak via retrograde flow from
the celiac artery. For treatment of these endoleaks, an
embolization procedure can be performed via a transfemo-
ral approach. An angled/directional catheter is directed
between the stent graft and the aortic wall and used to
access the aneurysm sac. The catheter is placed in proximity
to the celiac artery and/or the endoleak channel and ap-
propriately sized coils are selectively deployed. If a persis-
tent type II endoleak from celiac artery is suspected prior to
TEVAR, selective coil embolization of the celiac artery can
be performed prior to or during TEVAR.
CONCLUSION
In conclusion, TEVAR has become an acceptable
means for managing patients with TAA and is generally
considered to be associated with less morbidity and mor-
tality compared with open surgical repair of complex tho-
racic aortic aneurysms. Our initial experience of 31 patients
with celiac artery coverage during TEVAR suggests an
acceptably low incidence of visceral ischemic complications
in select patients with demonstrable pancreaticoduodenal
and gastroduodenal arterial collaterals between the celiac
and SMA. We believe preoperative CTA and selective vis-
ceral angiography are complementary in identifying visceral
collateral circulation and should be thoroughly evaluated
until we fully recognize the strengths and limitations of
these procedures in predicting visceral ischemia. Patients
with planned celiac artery stent graft coverage that have
preexisting severe SMA stenosis should be considered for
SMA stent placement at the time of TEVAR to optimize
visceral collateral circulation. Although these results are
promising, currently available data only suggests that celiac
artery coverage to facilitate lengthening the distal stent
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tality in select patients, and its long-term efficacy remains to
be evaluated. Finally, it is obvious that the ideal thoracic
stent graft for treating these complex thoracic aortic aneu-
rysms is not yet available, and although future modifica-
tions in stent graft design that are inclusive of fenestrations
and branch graft technology appear promising, for the time
being these devices are not readily available. Currently,
available data on SMA stenting in patients with visceral
ischemia suggest 20% to 40% in-stent stenosis at mean
follow-up of 3 to 5 years, and there is the possibility of
patients developing delayed mesenteric ischemia at long-
term follow-up.15-17 Therefore, it is vital that patients that
undergo these complex procedures undergo vigilant long-
term follow-up to assess not only for the stent graft integ-
rity, but also for the SMA stents in select patients.
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